Xeris Biopharma Holdings Inc expected to post a loss of 9 cents a share - Earnings Preview

Xeris Biopharma Holdings

06/11/2024 14:10

* Xeris Biopharma Holdings Inc  XERS.OQ   XERS.O  is
expected
to show a rise in quarterly revenue when it reports  results on
November 8 for the period ending September 30 2024
    * The Chicago Illinois-based  company is expected to report
a
6.4% increase in revenue to $51.433 million from $48.32 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Xeris Biopharma Holdings
Inc
is for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Xeris
Biopharma
Holdings Inc is 5.00​, above​ its last closing price of $3.26.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.11       -0.11      -0.10     Beat    6.3
 Mar. 31 2024  -0.12       -0.12      -0.14     Missed  -20
 Jan. 1 0001   -0.10       -0.10      -0.10     Met     -2​
 Sep. 30 2023  -0.12       -0.12      -0.09     Beat    22.4
 ​​Jun.        -0.13       -0.13      -0.14     Missed  -9.8
 30 2023                                                
 Jan. 1 0001   -0.17       -0.17      -0.12     Beat    28.4​
 Jan. 1 0001   -0.16       -0.16      -0.10     Beat    36.5
 Sep. 30 2022  -0.17       -0.16      -0.16     Met     3
 This summary was machine generated November 6 at 14:10 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)